{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:04:28Z","timestamp":1790741068043,"version":"4.1.0"},"reference-count":327,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["journal-of-hepatology.eu","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1016\/j.jhep.2015.06.030","type":"journal-article","created":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T08:21:53Z","timestamp":1441095713000},"page":"971-1004","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1120,"title":["EASL Clinical Practice Guidelines: Autoimmune hepatitis"],"prefix":"10.1016","volume":"63","member":"78","reference":[{"key":"10.1016\/j.jhep.2015.06.030_b0005","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1001\/jama.281.20.1900","article-title":"Are guidelines following guidelines? The methodological quality of clinical practice guidelines in the peer-reviewed medical literature","volume":"281","author":"Shaneyfelt","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.jhep.2015.06.030_b0010","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1056\/NEJMra050408","article-title":"Autoimmune hepatitis","volume":"354","author":"Krawitt","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2015.06.030_b0015","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jhep.2010.12.012","article-title":"Autoimmune hepatitis","volume":"55","author":"Lohse","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.06.030_b0020","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1111\/apt.12470","article-title":"Review article: autoimmune hepatitis \u2013 Current management and challenges","volume":"38","author":"Zachou","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2015.06.030_b0025","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jhep.2015.03.005","article-title":"Autoimmune hepatitis \u2013 Update 2015","volume":"62","author":"Manns","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.06.030_b0030","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1080\/00365529850166284","article-title":"Incidence and prevalence of primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis in a Norwegian population","volume":"33","author":"Boberg","year":"1998","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.jhep.2015.06.030_b0035","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1046\/j.1440-1746.2003.03165.x","article-title":"Epidemiology of autoimmune liver disease","volume":"18","author":"Feld","year":"2003","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2015.06.030_b0040","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1080\/00365520802130183","article-title":"Epidemiology and the initial presentation of autoimmune hepatitis in Sweden: a nationwide study","volume":"43","author":"Werner","year":"2008","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.jhep.2015.06.030_b0045","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1111\/j.1440-1746.2010.06384.x","article-title":"Population-based epidemiology study of autoimmune hepatitis: a disease of older women?","volume":"25","author":"Ngu","year":"2010","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2015.06.030_b0050","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1111\/1751-2980.12085","article-title":"Autoimmune hepatitis in southern Israel: a 15-year multicenter study","volume":"14","author":"Delgado","year":"2013","journal-title":"J Dig Dis"},{"key":"10.1016\/j.jhep.2015.06.030_b0055","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.3109\/00365521.2014.946083","article-title":"Epidemiology and clinical characteristics of autoimmune hepatitis in the Netherlands","volume":"49","author":"van Gerven","year":"2014","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.jhep.2015.06.030_b0060","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1111\/j.1572-0241.2002.06019.x","article-title":"Prevalence of autoimmune liver disease in Alaska Natives","volume":"97","author":"Hurlburt","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2015.06.030_b0065","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.jhep.2013.10.020","article-title":"Autoimmune hepatitis in Denmark: incidence, prevalence, prognosis, and causes of death. A nationwide registry-based cohort study","volume":"60","author":"Gr\u00f8nb\u00e6k","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.06.030_b0070","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1155\/2008\/642432","article-title":"Autoimmune hepatitis in a North American Aboriginal\/First Nations population","volume":"22","author":"Minuk","year":"2008","journal-title":"Can J Gastroenterol"},{"key":"10.1016\/j.jhep.2015.06.030_b0075","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1002\/hep.21884","article-title":"The impact of ethnicity on the natural history of autoimmune hepatitis","volume":"46","author":"Verma","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.06.030_b0080","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1111\/j.1572-0241.2001.05272.x","article-title":"Autoimmune hepatitis in African Americans: presenting features and response to therapy","volume":"96","author":"Lim","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2015.06.030_b0085","doi-asserted-by":"crossref","first-page":"543","DOI":"10.3109\/08916934.2011.592884","article-title":"Performance of the international classifications criteria for autoimmune hepatitis diagnosis in Mexican patients","volume":"44","author":"Munoz-Espinosa","year":"2011","journal-title":"Autoimmunity"},{"key":"10.1016\/j.jhep.2015.06.030_b0090","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/MCG.0b013e318228b781","article-title":"The impact of race\/ethnicity on the clinical epidemiology of autoimmune hepatitis","volume":"46","author":"Wong","year":"2012","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.jhep.2015.06.030_b0095","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1016\/j.cgh.2013.12.010","article-title":"Hispanics with primary biliary cirrhosis are more likely to have features of autoimmune hepatitis and reduced response to ursodeoxycholic acid than non-Hispanics","volume":"12","author":"Levy","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2015.06.030_b0100","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1136\/gut.50.5.713","article-title":"Characteristics of autoimmune hepatitis in patients who are not of European Caucasoid ethnic origin","volume":"50","author":"Zolfino","year":"2002","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2015.06.030_b0105","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1586\/egh.13.21","article-title":"Autoimmune hepatitis in diverse ethnic populations and geographical regions","volume":"7","author":"Czaja","year":"2013","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2015.06.030_b0110","first-page":"113","article-title":"Blutproteine und Nahrungseiweiss","volume":"15","author":"Leber","year":"1950","journal-title":"Deutsch Z Verdau Stoffwechselkr"},{"key":"10.1016\/j.jhep.2015.06.030_b0115","first-page":"654","article-title":"Extreme hypergammaglobulinemia in young women with liver disease of unknown etiology","volume":"30","author":"Kunkel","year":"1951","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jhep.2015.06.030_b0120","first-page":"1323","article-title":"Lupoid hepatitis","volume":"271","author":"Cowling","year":"1956","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2015.06.030_b0125","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1111\/j.1749-6632.1965.tb19000.x","article-title":"Autoimmune hepatitis","volume":"124","author":"Mackay","year":"1965","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.jhep.2015.06.030_b0130","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1002\/hep.1840180435","article-title":"Meeting report: International Autoimmune Hepatitis Group","volume":"18","author":"Johnson","year":"1993","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.06.030_b0135","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/S0168-8278(99)80297-9","article-title":"International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis","volume":"31","author":"Alvarez","year":"1999","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.06.030_b0140","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/hep.22322","article-title":"Simplified criteria for the diagnosis of autoimmune hepatitis","volume":"48","author":"Hennes","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.06.030_b0145","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1016\/j.jhep.2009.01.020","article-title":"Autoimmune hepatitis in Italy: the Bologna experience","volume":"50","author":"Muratori","year":"2009","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.06.030_b0150","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1111\/j.1572-0241.2001.03782.x","article-title":"Autoimmune hepatitis in the elderly","volume":"96","author":"Schramm","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2015.06.030_b0155","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3892\/etm.2013.1363","article-title":"Clinical features in different age groups of patients with autoimmune hepatitis","volume":"7","author":"Peng","year":"2014","journal-title":"Exp Ther Med"},{"key":"10.1016\/j.jhep.2015.06.030_b0160","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/apt.12563","article-title":"Systematic review with meta-analysis: clinical manifestations and management of autoimmune hepatitis in the elderly","volume":"39","author":"Chen","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2015.06.030_b0165","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1007\/s00535-011-0421-y","article-title":"Present status of autoimmune hepatitis in Japan: a nationwide survey","volume":"46","author":"Abe","year":"2011","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.jhep.2015.06.030_b0170","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1002\/hep.23584","article-title":"Diagnosis and management of autoimmune hepatitis","volume":"51","author":"Manns","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.06.030_b0175","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.jhep.2006.04.007","article-title":"Autoimmune hepatitis (AIH) in the elderly: a systematic retrospective analysis of a large group of consecutive patients with definite AIH followed at a tertiary referral centre","volume":"45","author":"Al-Chalabi","year":"2006","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.06.030_b0180","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.jhep.2013.10.035","article-title":"Health-related quality of life, depression, and anxiety in patients with autoimmune hepatitis","volume":"60","author":"Schramm","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.06.030_b0185","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1002\/hep.24080","article-title":"Autoimmune acute liver failure: proposed clinical and histological criteria","volume":"53","author":"Stravitz","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.06.030_b0190","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1111\/j.1872-034X.2011.00808.x","article-title":"Acute presentation of autoimmune hepatitis: Does it exist? A published work review","volume":"41","author":"Takahashi","year":"2011","journal-title":"Hepatol Res"},{"key":"10.1016\/j.jhep.2015.06.030_b0195","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1093\/qjmed\/hch072","article-title":"Type 1 autoimmune hepatitis: patterns of clinical presentation and differential diagnosis of the \u2018acute\u2019 type","volume":"97","author":"Ferrari","year":"2004","journal-title":"QJM"},{"key":"10.1016\/j.jhep.2015.06.030_b0200","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1136\/gut.2010.235259","article-title":"British Society of Gastroenterology (BSG) guidelines for management of autoimmune hepatitis","volume":"60","author":"Gleeson","year":"2011","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2015.06.030_b0205","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.bpg.2011.09.011","article-title":"Autoimmune hepatitis in special patient populations","volume":"25","author":"Czaja","year":"2011","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"10.1016\/j.jhep.2015.06.030_b0210","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1111\/j.1365-2036.2006.02894.x","article-title":"Clinical characteristics of fulminant-type autoimmune hepatitis: an analysis of eleven cases","volume":"23","author":"Miyake","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2015.06.030_b0215","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1002\/hep.26678","article-title":"Steroid use in acute liver failure","volume":"59","author":"Karkhanis","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.06.030_b0220","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/hep.20732","article-title":"Autoimmune hepatitis: effect of symptoms and cirrhosis on natural history and outcome","volume":"42","author":"Feld","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.06.030_b0225","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.jhep.2010.12.032","article-title":"Mycophenolate for the treatment of autoimmune hepatitis: prospective assessment of its efficacy and safety for induction and maintenance of remission in a large cohort of treatment-naive patients","volume":"55","author":"Zachou","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.06.030_b0230","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/S1665-2681(19)31493-0","article-title":"Effect of cirrhosis at baseline on the outcome of type 1 autoimmune hepatitis","volume":"11","author":"Landeira","year":"2012","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.jhep.2015.06.030_b0235","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1002\/hep.26290","article-title":"Predictors of poor outcome in patients with autoimmune hepatitis: a population-based study","volume":"57","author":"Ngu","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.06.030_b0240","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/S0140-6736(87)92024-1","article-title":"Characterisation of a new subgroup of autoimmune chronic active hepatitis by autoantibodies against a soluble liver antigen","volume":"1","author":"Manns","year":"1987","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2015.06.030_b0245","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0168-8278(99)80342-0","article-title":"Clinical significance of autoantibodies to soluble liver antigen in autoimmune hepatitis","volume":"31","author":"Kanzler","year":"1999","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.06.030_b0250","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/j.1572-0241.2002.05479.x","article-title":"Antibodies to soluble liver antigen\/liver pancreas and HLA risk factors for type 1 autoimmune hepatitis","volume":"97","author":"Czaja","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2015.06.030_b0255","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.jhep.2010.09.002","article-title":"Overlap syndromes: the International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue","volume":"54","author":"Boberg","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.06.030_b0260","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1053\/jhep.2001.22131","article-title":"Autoimmune hepatitis\/sclerosing cholangitis overlap syndrome in childhood: a 16-year prospective study","volume":"33","author":"Gregorio","year":"2001","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.06.030_b0265","doi-asserted-by":"crossref","first-page":"202","DOI":"10.3109\/15513815.2014.898721","article-title":"Autoimmune hepatitis and primary sclerosing cholangitis in children and adolescents","volume":"33","author":"Rojas","year":"2014","journal-title":"Fetal Pediatr Pathol"},{"key":"10.1016\/j.jhep.2015.06.030_b0270","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1097\/MPG.0b013e3181a1c265","article-title":"Autoimmune hepatitis","volume":"49","author":"Mieli-Vergani","year":"2009","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.jhep.2015.06.030_b0275","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.dld.2010.03.005","article-title":"Comparison of simplified score with the revised original score for the diagnosis of autoimmune hepatitis: a new or a complementary diagnostic score?","volume":"42","author":"Gatselis","year":"2010","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.jhep.2015.06.030_b0280","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1002\/hep.510290409","article-title":"Characterization of the overlap syndrome of primary biliary cirrhosis (PBC) and autoimmune hepatitis: evidence for it being a hepatitic form of PBC in genetically susceptible individuals","volume":"29","author":"Lohse","year":"1999","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.06.030_b0285","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1002\/hep.510280203","article-title":"Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy","volume":"28","author":"Chazouilleres","year":"1998","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.06.030_b0290","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0399-8320(07)89323-7","article-title":"Overlap syndrome of primary biliary cirrhosis and autoimmune hepatitis: a retrospective study of 115 cases of autoimmune liver disease","volume":"31","author":"Heurgue","year":"2007","journal-title":"Gastroenterol Clin Biol"},{"key":"10.1016\/j.jhep.2015.06.030_b0295","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.cgh.2010.03.004","article-title":"Paris criteria are effective in diagnosis of primary biliary cirrhosis and autoimmune hepatitis overlap syndrome","volume":"8","author":"Kuiper","year":"2010","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2015.06.030_b0300","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.jhep.2009.04.009","article-title":"EASL Clinical Practice Guidelines: management of cholestatic liver diseases","volume":"51","year":"2009","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.06.030_b0305","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/S0168-8278(96)80266-2","article-title":"Evidence for an overlap syndrome of autoimmune hepatitis and primary sclerosing cholangitis","volume":"24","author":"Gohlke","year":"1996","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.06.030_b0310","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1002\/hep.23024","article-title":"Prevalence of sclerosing cholangitis in adults with autoimmune hepatitis: a prospective magnetic resonance imaging and histological study","volume":"50","author":"Lewin","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.06.030_b0315","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1053\/jhep.2001.27562","article-title":"Autoimmune hepatitis with incidental histologic features of bile duct injury","volume":"34","author":"Czaja","year":"2001","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.06.030_b0320","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/MCG.0b013e318157c614","article-title":"Characteristics and long-term prognosis of the autoimmune hepatitis\/primary sclerosing cholangitis overlap syndrome","volume":"43","author":"Luth","year":"2009","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.jhep.2015.06.030_b0325","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.jhep.2014.08.002","article-title":"Long-term outcome in PSC\/AIH \u201coverlap syndrome\u201d: does immunosuppression also treat the PSC component?","volume":"61","author":"Zenouzi","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.06.030_b0330","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/j.1478-3231.2009.02092.x","article-title":"Identification and characterization of IgG4-associated autoimmune hepatitis","volume":"30","author":"Chung","year":"2010","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2015.06.030_b0335","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1007\/s00535-010-0323-4","article-title":"Clinical significance of immunoglobulin G4-associated autoimmune hepatitis","volume":"46","author":"Umemura","year":"2011","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.jhep.2015.06.030_b0340","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1111\/j.1365-2036.2012.05223.x","article-title":"Review article: overlap syndromes and autoimmune liver disease","volume":"36","author":"Trivedi","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2015.06.030_b0345","doi-asserted-by":"crossref","first-page":"160","DOI":"10.4254\/wjh.v6.i4.160","article-title":"Drug-induced autoimmune liver disease: a diagnostic dilemma of an increasingly reported disease","volume":"6","author":"Castiella","year":"2014","journal-title":"World J Hepatol"},{"key":"10.1016\/j.jhep.2015.06.030_b0350","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.jhep.2011.02.024","article-title":"Drug induced liver injury and its relationship to autoimmune hepatitis","volume":"55","author":"Weiler-Normann","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.06.030_b0355","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1073\/pnas.84.2.551","article-title":"Human anti-endoplasmic reticulum autoantibodies appearing in a drug-induced hepatitis are directed against a human liver cytochrome P-450 that hydroxylates the drug","volume":"84","author":"Beaune","year":"1987","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jhep.2015.06.030_b0360","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1172\/JCI114660","article-title":"Anti-liver endoplasmic reticulum autoantibodies are directed against human cytochrome P-450IA2. A specific marker of dihydralazine-induced hepatitis","volume":"85","author":"Bourdi","year":"1990","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jhep.2015.06.030_b0365","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1186\/1752-1947-4-311","article-title":"Autoimmune hepatitis triggered by nitrofurantoin: a case series","volume":"4","author":"Appleyard","year":"2010","journal-title":"J Med Case Rep"},{"key":"10.1016\/j.jhep.2015.06.030_b0370","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1002\/hep.23588","article-title":"Drug-induced autoimmune hepatitis: clinical characteristics and prognosis","volume":"51","author":"Bjornsson","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.06.030_b0375","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1002\/hep.24481","article-title":"The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury","volume":"54","author":"Suzuki","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.06.030_b0380","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1002\/hep.23696","article-title":"Standardization of nomenclature and causality assessment in drug-induced liver injury: summary of a clinical research workshop","volume":"52","author":"Fontana","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.06.030_b0385","first-page":"A271","article-title":"Drug-induced autoimmune hepatitis: a frequent disorder","volume":"56","author":"Heurgu\u00e9","year":"2007","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2015.06.030_b0390","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1053\/j.gastro.2008.09.011","article-title":"Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States","volume":"135","author":"Chalasani","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2015.06.030_b0395","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.1111\/j.1572-0241.2002.07124.x","article-title":"Improvement of autoimmune hepatitis during pregnancy followed by flare-up after delivery","volume":"97","author":"Buchel","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2015.06.030_b0400","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/S1542-3565(04)00245-9","article-title":"Severe autoimmune hepatitis first presenting in the early post partum period","volume":"2","author":"Samuel","year":"2004","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2015.06.030_b0405","doi-asserted-by":"crossref","first-page":"J239","DOI":"10.1016\/j.jaut.2011.12.002","article-title":"Outcomes of pregnancy in women with autoimmune hepatitis","volume":"38","author":"Westbrook","year":"2012","journal-title":"J Autoimmun"},{"key":"10.1016\/j.jhep.2015.06.030_b0410","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1136\/gut.48.1.97","article-title":"Management and outcome of pregnancy in autoimmune hepatitis","volume":"48","author":"Heneghan","year":"2001","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2015.06.030_b0415","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/S1590-8658(02)80098-6","article-title":"Spontaneous remission of autoimmune hepatitis during pregnancy","volume":"34","author":"Muratori","year":"2002","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.jhep.2015.06.030_b0420","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1097\/MCG.0b013e318176b8c5","article-title":"Follow-up of pregnant women with autoimmune hepatitis: the disease behavior along with maternal and fetal outcomes","volume":"43","author":"Terrabuio","year":"2009","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.jhep.2015.06.030_b0425","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S1568-9972(03)00053-3","article-title":"Is there a role for viruses in triggering autoimmune hepatitis?","volume":"3","author":"Vento","year":"2004","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.jhep.2015.06.030_b0430","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S1665-2681(19)31398-5","article-title":"Autoimmune hepatitis type-2 and Epstein-Barr virus infection in a toddler: art of facts or an artifact?","volume":"12","author":"Zellos","year":"2013","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.jhep.2015.06.030_b0435","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/S0168-8278(99)80092-0","article-title":"Epitope mapping of cytochrome P4502D6 autoantigen in patients with chronic hepatitis C during alpha-interferon treatment","volume":"30","author":"Dalekos","year":"1999","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.06.030_b0440","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S0168-8278(05)80395-2","article-title":"Interferon therapy in liver\/kidney microsomal antibody type 1-positive patients with chronic hepatitis C","volume":"21","author":"Muratori","year":"1994","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.06.030_b0445","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1016\/S0140-6736(05)62476-2","article-title":"Autoimmune hepatitis type 2 induced by HCV and persisting after viral clearance","volume":"350","author":"Vento","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2015.06.030_b0450","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jhep.2003.10.022","article-title":"De novo autoimmune hepatitis after liver transplantation","volume":"40","author":"Mieli-Vergani","year":"2004","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.06.030_b0455","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1111\/j.1478-3231.2012.02832.x","article-title":"Incidence and risk factors associated with de novo autoimmune hepatitis after liver transplantation","volume":"32","author":"Montano-Loza","year":"2012","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2015.06.030_b0460","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1097\/MOT.0b013e3283536622","article-title":"Plasma cell hepatitis (de-novo autoimmune hepatitis) developing post liver transplantation","volume":"17","author":"Fiel","year":"2012","journal-title":"Curr Opin Organ Transplant"},{"key":"10.1016\/j.jhep.2015.06.030_b0465","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.semarthrit.2006.11.005","article-title":"How common are connective tissue disorders in patients with autoimmune hepatitis?","volume":"36","author":"Rigopoulou","year":"2007","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.jhep.2015.06.030_b0470","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2165\/11593150-000000000-00000","article-title":"Celiac disease in pediatric patients with autoimmune hepatitis: etiology, diagnosis, and management","volume":"14","author":"Panetta","year":"2012","journal-title":"Paediatr Drugs"},{"key":"10.1016\/j.jhep.2015.06.030_b0475","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1097\/MCG.0b013e3181c74e0d","article-title":"Concurrent autoimmune diseases in patients with autoimmune hepatitis","volume":"44","author":"Teufel","year":"2010","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.jhep.2015.06.030_b0480","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1053\/gast.2001.27103","article-title":"Hepatic autoantigens in patients with autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy","volume":"121","author":"Obermayer-Straub","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2015.06.030_b0485","doi-asserted-by":"crossref","first-page":"578","DOI":"10.3748\/wjg.15.578","article-title":"Hepatocellular carcinoma in patients with autoimmune hepatitis","volume":"15","author":"Teufel","year":"2009","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jhep.2015.06.030_b0490","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1002\/hep.22432","article-title":"Evaluation of risk factors in the development of hepatocellular carcinoma in autoimmune hepatitis: implications for follow-up and screening","volume":"48","author":"Yeoman","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.06.030_b0495","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1002\/hep.24743","article-title":"Mortality and the risk of malignancy in autoimmune liver diseases: a population-based study in Canterbury, New Zealand","volume":"55","author":"Ngu","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.06.030_b0500","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1111\/j.1478-3231.2011.02734.x","article-title":"Hepatocellular carcinoma and survival in patients with autoimmune hepatitis (Japanese National Hospital Organization-autoimmune hepatitis prospective study)","volume":"32","author":"Migita","year":"2012","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2015.06.030_b0505","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1111\/j.1572-0241.2008.01922.x","article-title":"Predictive factors for hepatocellular carcinoma in type 1 autoimmune hepatitis","volume":"103","author":"Montano-Loza","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2015.06.030_b0510","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s00535-011-0519-2","article-title":"Risk factors for hepatocellular carcinoma in Japanese patients with autoimmune hepatitis type 1","volume":"47","author":"Hino-Arinaga","year":"2012","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.jhep.2015.06.030_b0515","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1007\/s10620-012-2525-5","article-title":"Hepatocellular carcinoma and other malignancies in autoimmune hepatitis","volume":"58","author":"Czaja","year":"2013","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jhep.2015.06.030_b0520","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jhep.2007.08.013","article-title":"Impact of gender on the long-term outcome and survival of patients with autoimmune hepatitis","volume":"48","author":"Al-Chalabi","year":"2008","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.06.030_b0525","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1111\/j.1365-2036.2006.03104.x","article-title":"Type I autoimmune hepatitis: clinical course and outcome in an Italian multicentre study","volume":"24","author":"Floreani","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2015.06.030_b0530","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1007\/s00535-008-2254-x","article-title":"Precise histological evaluation of liver biopsy specimen is indispensable for diagnosis and treatment of acute-onset autoimmune hepatitis","volume":"43","author":"Fujiwara","year":"2008","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.jhep.2015.06.030_b0535","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1007\/s00535-010-0316-3","article-title":"Clinicopathological features of severe and fulminant forms of autoimmune hepatitis","volume":"46","author":"Yasui","year":"2011","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.jhep.2015.06.030_b0540","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1097\/MCG.0b013e318154af74","article-title":"Serologic markers compared with liver biopsy for monitoring disease activity in autoimmune hepatitis","volume":"42","author":"Luth","year":"2008","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.jhep.2015.06.030_b0545","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1111\/j.1478-3231.2008.01851.x","article-title":"Occult hepatitis B virus infection in patients with autoimmune liver diseases","volume":"29","author":"Georgiadou","year":"2009","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2015.06.030_b0550","first-page":"233","article-title":"A new approach for treatment of hepatitis C in hepatitis C-autoimmune hepatitis overlap syndrome","volume":"6","author":"Azhar","year":"2010","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"10.1016\/j.jhep.2015.06.030_b0555","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S1665-2681(19)30914-7","article-title":"Autoimmune hepatitis in patients with chronic HBV and HCV infections: patterns of clinical characteristics, disease progression and outcome","volume":"13","author":"Rigopoulou","year":"2013","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.jhep.2015.06.030_b0560","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.jhep.2004.08.002","article-title":"Liver autoimmune serology: a consensus statement from the committee for autoimmune serology of the International Autoimmune Hepatitis Group","volume":"41","author":"Vergani","year":"2004","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.06.030_b0565","doi-asserted-by":"crossref","first-page":"3374","DOI":"10.3748\/wjg.14.3374","article-title":"Autoimmune liver serology: current diagnostic and clinical challenges","volume":"14","author":"Bogdanos","year":"2008","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jhep.2015.06.030_b0570","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1053\/gast.2001.20223","article-title":"Autoantibodies in liver disease","volume":"120","author":"Czaja","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2015.06.030_b0575","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1111\/j.1572-0241.2006.00830.x","article-title":"Evaluation of F-actin ELISA for the diagnosis of autoimmune hepatitis","volume":"101","author":"Frenzel","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2015.06.030_b0580","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1080\/08916930701619896","article-title":"Diagnostic accuracy of four different immunological methods for the detection of anti-F-actin autoantibodies in type 1 autoimmune hepatitis and other liver-related disorders","volume":"41","author":"Villalta","year":"2008","journal-title":"Autoimmunity"},{"key":"10.1016\/j.jhep.2015.06.030_b0585","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1136\/jcp.2005.027367","article-title":"Antibodies to filamentous actin (F-actin) in type 1 autoimmune hepatitis","volume":"59","author":"Granito","year":"2006","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.jhep.2015.06.030_b0590","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1136\/jcp.2006.039404","article-title":"Diagnostic relevance of anti-filamentous actin antibodies in autoimmune hepatitis","volume":"60","author":"Liaskos","year":"2007","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.jhep.2015.06.030_b0595","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1002\/hep.510260305","article-title":"Serum autoantibodies in chronic hepatitis C: comparison with autoimmune hepatitis and impact on the disease profile","volume":"26","author":"Cassani","year":"1997","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.06.030_b0600","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/S0168-8278(96)80228-5","article-title":"Non-organ specific autoantibodies in children with chronic hepatitis C","volume":"25","author":"Bortolotti","year":"1996","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.06.030_b0605","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1136\/gut.36.5.749","article-title":"Liver cytosolic 1 antigen-antibody system in type 2 autoimmune hepatitis and hepatitis C virus infection","volume":"36","author":"Lenzi","year":"1995","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2015.06.030_b0610","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/00042737-200201000-00007","article-title":"Increased incidence of anti-LKM autoantibodies in a consecutive cohort of hepatitis C patients from central Greece","volume":"14","author":"Dalekos","year":"2002","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2015.06.030_b0615","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/j.jhep.2009.02.020","article-title":"Clinical features and effect of antiviral therapy on anti-liver\/kidney microsomal antibody type 1 positive chronic hepatitis C","volume":"50","author":"Ferri","year":"2009","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.06.030_b0620","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.4049\/jimmunol.170.3.1481","article-title":"Cytochrome P4502D6(193\u2013212): a new immunodominant epitope and target of virus\/self cross-reactivity in liver kidney microsomal autoantibody type 1-positive liver disease","volume":"170","author":"Kerkar","year":"2003","journal-title":"J Immunol"},{"key":"10.1016\/j.jhep.2015.06.030_b0625","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0168-8278(99)80175-5","article-title":"Development of cytochrome P450 2D6-specific LKM-autoantibodies following liver transplantation for Wilson\u2019s disease \u2013 Possible association with a steroid-resistant transplant rejection episode","volume":"31","author":"Lohse","year":"1999","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.06.030_b0630","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1016\/S0140-6736(00)02166-8","article-title":"Identification of target antigen for SLA\/LP autoantibodies in autoimmune hepatitis","volume":"355","author":"Wies","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2015.06.030_b0635","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1126\/science.1173755","article-title":"The human SepSecS-tRNASec complex reveals the mechanism of selenocysteine formation","volume":"325","author":"Palioura","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.jhep.2015.06.030_b0640","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1136\/gut.51.2.259","article-title":"Establishment of standardised SLA\/LP immunoassays: specificity for autoimmune hepatitis, worldwide occurrence, and clinical characteristics","volume":"51","author":"Baeres","year":"2002","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2015.06.030_b0645","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1111\/liv.12658","article-title":"Anti-SLA\/LP alone or in combination with anti-Ro52 and fine specificity of anti-Ro52 antibodies in patients with autoimmune hepatitis","volume":"35","author":"Zachou","year":"2015","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2015.06.030_b0650","doi-asserted-by":"crossref","first-page":"S250","DOI":"10.1016\/S0168-8278(07)62258-2","article-title":"Antibody responses specific for soluble liver antigen co-occur with RO-52 autoantibodies in patients with autoimmune hepatitis","volume":"46","author":"Liaskos","year":"2007","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.06.030_b0655","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1111\/j.1478-3231.2009.01986.x","article-title":"Significance of antibodies to soluble liver antigen\/liver pancreas: a large French study","volume":"29","author":"Eyraud","year":"2009","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2015.06.030_b0660","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/j.1478-3231.2011.02502.x","article-title":"Prognostic implications of antibodies to Ro\/SSA and soluble liver antigen in type 1 autoimmune hepatitis","volume":"32","author":"Montano-Loza","year":"2012","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2015.06.030_b0665","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1053\/jhep.2002.32092","article-title":"Antibodies to conformational epitopes of soluble liver antigen define a severe form of autoimmune liver disease","volume":"35","author":"Ma","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.06.030_b0670","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1080\/08916930410001702469","article-title":"Nonstandard antibodies as prognostic markers in autoimmune hepatitis","volume":"37","author":"Czaja","year":"2004","journal-title":"Autoimmunity"},{"key":"10.1016\/j.jhep.2015.06.030_b0675","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/0016-5085(95)90215-5","article-title":"High-titer antineutrophil cytoplasmic antibodies in type-1 autoimmune hepatitis","volume":"108","author":"Targan","year":"1995","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2015.06.030_b0680","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1002\/hep.510250510","article-title":"Anti-neutrophil cytoplasmic antibodies in type 1 and 2 autoimmune hepatitis","volume":"25","author":"Zauli","year":"1997","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.06.030_b0685","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1053\/gast.2000.9366","article-title":"\u201cAtypical p-ANCA\u201d in IBD and hepatobiliary disorders react with a 50-kilodalton nuclear envelope protein of neutrophils and myeloid cell lines","volume":"119","author":"Terjung","year":"2000","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2015.06.030_b0690","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1046\/j.1365-2249.2001.01649.x","article-title":"Differentiation of antineutrophil nuclear antibodies in inflammatory bowel and autoimmune liver diseases from antineutrophil cytoplasmic antibodies (p-ANCA) using immunofluorescence microscopy","volume":"126","author":"Terjung","year":"2001","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jhep.2015.06.030_b0695","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1002\/hep.22380","article-title":"Long-term follow-up of antimitochondrial antibody-positive autoimmune hepatitis","volume":"48","author":"O\u2019Brien","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.06.030_b0700","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1111\/j.1440-1746.2006.04130.x","article-title":"Applicability of the IAIHG scoring system to the diagnosis of antimitochondrial\/anti-M2 seropositive variant form of autoimmune hepatitis","volume":"21","author":"Farias","year":"2006","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2015.06.030_b0705","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1136\/jcp.55.12.906","article-title":"Detection of liver kidney microsomal type 1 antibody using molecularly based immunoassays","volume":"55","author":"Kerkar","year":"2002","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.jhep.2015.06.030_b0710","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1007\/s10620-006-9665-4","article-title":"Corticosteroid-responsive cryptogenic chronic hepatitis: evidence for seronegative autoimmune hepatitis","volume":"52","author":"Gassert","year":"2007","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jhep.2015.06.030_b0715","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1055\/s-2006-927280","article-title":"Steroid treatment for severe acute cryptogenic hepatitis","volume":"45","author":"Potthoff","year":"2007","journal-title":"Z Gastroenterol"},{"key":"10.1016\/j.jhep.2015.06.030_b0720","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/S0168-8278(99)80096-8","article-title":"Behavior and significance of autoantibodies in type 1 autoimmune hepatitis","volume":"30","author":"Czaja","year":"1999","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.06.030_b0725","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1080\/0891693021000056721","article-title":"Organ and non-organ specific autoantibody titres and IgG levels as markers of disease activity: a longitudinal study in childhood autoimmune liver disease","volume":"35","author":"Gregorio","year":"2002","journal-title":"Autoimmunity"},{"key":"10.1016\/j.jhep.2015.06.030_b0730","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1136\/gut.42.5.721","article-title":"Liver\/kidney microsomal antibody type 1 and liver cytosol antibody type 1 concentrations in type 2 autoimmune hepatitis","volume":"42","author":"Muratori","year":"1998","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2015.06.030_b0735","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/01.mcg.0000225612.86846.82","article-title":"Prospective randomized comparison of minilaparoscopy and percutaneous liver biopsy: diagnosis of cirrhosis and complications","volume":"41","author":"Denzer","year":"2007","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.jhep.2015.06.030_b0740","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1111\/j.1572-0241.2003.07342.x","article-title":"Liver assessment and biopsy in patients with marked coagulopathy: value of mini-laparoscopy and control of bleeding","volume":"98","author":"Denzer","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2015.06.030_b0745","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1055\/s-2007-1001417","article-title":"Safety and feasibility of a new minimally invasive diagnostic laparoscopy technique","volume":"30","author":"Helmreich-Becker","year":"1998","journal-title":"Endoscopy"},{"key":"10.1016\/j.jhep.2015.06.030_b0750","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1016\/0016-5085(93)91081-R","article-title":"Sensitivity, specificity, and predictability of biopsy interpretations in chronic hepatitis","volume":"105","author":"Czaja","year":"1993","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2015.06.030_b0755","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/j.cgh.2007.05.031","article-title":"Optimizing diagnosis from the medical liver biopsy","volume":"5","author":"Czaja","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2015.06.030_b0760","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1002\/hep.1840190629","article-title":"Classification of chronic hepatitis: diagnosis, grading and staging","volume":"19","author":"Desmet","year":"1994","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.06.030_b0765","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/S1089-3261(02)00007-7","article-title":"Autoimmune hepatitis and overlap syndromes","volume":"6","author":"Dienes","year":"2002","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.jhep.2015.06.030_b0770","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/S1542-3565(04)00246-0","article-title":"Fulminant hepatic failure as the initial presentation of acute autoimmune hepatitis","volume":"2","author":"Kessler","year":"2004","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2015.06.030_b0775","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1097\/00000478-199506000-00010","article-title":"Recent-onset autoimmune hepatitis. Biopsy findings and clinical correlations","volume":"19","author":"Burgart","year":"1995","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.jhep.2015.06.030_b0780","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1136\/jcp.2005.029348","article-title":"Centrilobular necrosis in autoimmune hepatitis: a histological feature associated with acute clinical presentation","volume":"59","author":"Hofer","year":"2006","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.jhep.2015.06.030_b0785","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1016\/j.humpath.2007.03.019","article-title":"Hepatic centrilobular zonal necrosis with positive antinuclear antibody: a unique subtype or early disease of autoimmune hepatitis?","volume":"38","author":"Zen","year":"2007","journal-title":"Hum Pathol"},{"key":"10.1016\/j.jhep.2015.06.030_b0790","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S1386-6346(02)00274-7","article-title":"Clinicopathological features of acute-onset autoimmune hepatitis","volume":"25","author":"Okano","year":"2003","journal-title":"Hepatol Res"},{"key":"10.1016\/j.jhep.2015.06.030_b0795","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/j.1478-3231.2004.0924.x","article-title":"Diagnostic and therapeutic implications of bile duct injury in autoimmune hepatitis","volume":"24","author":"Czaja","year":"2004","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2015.06.030_b0800","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1007\/BF01076196","article-title":"Severe chronic active liver disease. Prognostic significance of initial morphologic patterns","volume":"22","author":"Schalm","year":"1977","journal-title":"Am J Dig Dis"},{"key":"10.1016\/j.jhep.2015.06.030_b0805","first-page":"7","article-title":"Minilaparoskopie in der Leberdiagnostik \u2013 ein Vorteil?","volume":"39","author":"Helmreich-Becker","year":"2001","journal-title":"Z Gastroenterol"},{"key":"10.1016\/j.jhep.2015.06.030_b0810","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1097\/MEG.0b013e328332dd0a","article-title":"Noninvasive markers of fibrosis and inflammation in clinical practice: prospective comparison with liver biopsy","volume":"22","author":"Anastasiou","year":"2010","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2015.06.030_b0815","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1111\/liv.12198","article-title":"Laboratory-based scoring system for prediction of hepatic inflammatory activity in patients with autoimmune hepatitis","volume":"33","author":"Gutkowski","year":"2013","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2015.06.030_b0820","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/S0168-8278(00)80004-5","article-title":"Overlap of autoimmune hepatitis and primary sclerosing cholangitis: an evaluation of a modified scoring system","volume":"33","author":"Kaya","year":"2000","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.06.030_b0825","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1111\/j.1572-0241.2002.05703.x","article-title":"Overlap of autoimmune hepatitis and primary biliary cirrhosis: an evaluation of a modified scoring system","volume":"97","author":"Talwalkar","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2015.06.030_b0830","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1002\/hep.22513","article-title":"Performance parameters of the diagnostic scoring systems for autoimmune hepatitis","volume":"48","author":"Czaja","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.06.030_b0835","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/BF02093820","article-title":"Validation of scoring system for diagnosis of autoimmune hepatitis","volume":"41","author":"Czaja","year":"1996","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jhep.2015.06.030_b0840","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.jhep.2010.06.032","article-title":"Validation of the simplified criteria for diagnosis of autoimmune hepatitis in Chinese patients","volume":"54","author":"Qiu","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.06.030_b0845","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1002\/hep.23042","article-title":"Diagnostic value and utility of the simplified International Autoimmune Hepatitis Group (IAIHG) criteria in acute and chronic liver disease","volume":"50","author":"Yeoman","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.06.030_b0850","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/ajg.2009.616","article-title":"Autoimmune hepatitis-PBC overlap syndrome: a simplified scoring system may assist in the diagnosis","volume":"105","author":"Neuhauser","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2015.06.030_b0855","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1038\/ajg.2009.126","article-title":"The serological profile of the autoimmune hepatitis\/primary biliary cirrhosis overlap syndrome","volume":"104","author":"Muratori","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2015.06.030_b0860","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.jhep.2010.07.013","article-title":"Recognizing autoimmune hepatitis: scores help, but no more","volume":"54","author":"Lohse","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.06.030_b0865","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1111\/j.1872-034X.2012.01109.x","article-title":"Prognosis of autoimmune hepatitis showing acute presentation","volume":"43","author":"Yamamoto","year":"2013","journal-title":"Hepatol Res"},{"key":"10.1016\/j.jhep.2015.06.030_b0870","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1111\/j.1478-3231.2011.02524.x","article-title":"Diagnostic value and utility of the simplified International Autoimmune Hepatitis Group criteria in acute-onset autoimmune hepatitis","volume":"31","author":"Fujiwara","year":"2011","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2015.06.030_b0875","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1093\/oxfordjournals.qjmed.a067264","article-title":"Controlled prospective trial of corticosteroid therapy in active chronic hepatitis","volume":"40","author":"Cook","year":"1971","journal-title":"Q J Med"},{"key":"10.1016\/j.jhep.2015.06.030_b0880","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/S0016-5085(19)33223-8","article-title":"Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis","volume":"63","author":"Soloway","year":"1972","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2015.06.030_b0885","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0140-6736(73)92125-9","article-title":"Controlled trial of prednisone and azathioprine in active chronic hepatitis","volume":"1","author":"Murray-Lyon","year":"1973","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2015.06.030_b0890","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1136\/gut.21.1.78","article-title":"Late results of the Royal Free Hospital prospective controlled trial of prednisolone therapy in hepatitis B surface antigen negative chronic active hepatitis","volume":"21","author":"Kirk","year":"1980","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2015.06.030_b0895","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.jhep.2010.01.037","article-title":"Treatment options for autoimmune hepatitis: a systematic review of randomized controlled trials","volume":"53","author":"Lamers","year":"2010","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.06.030_b0900","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1136\/gut.19.6.510","article-title":"Long-term follow-up of chronic active hepatitis of moderate severity","volume":"19","author":"De Groote","year":"1978","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2015.06.030_b0905","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1111\/j.1478-3231.2008.01904.x","article-title":"Features and consequences of untreated type 1 autoimmune hepatitis","volume":"29","author":"Czaja","year":"2009","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2015.06.030_b0910","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/S0168-8278(02)00329-X","article-title":"Severe autoimmune hepatitis in patients with previous spontaneous recovery of a flare","volume":"37","author":"Dufour","year":"2002","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.06.030_b0915","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/00004836-200207000-00016","article-title":"Prognosis of symptomatic versus asymptomatic autoimmune hepatitis: a study of 68 patients","volume":"35","author":"Kogan","year":"2002","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.jhep.2015.06.030_b0920","first-page":"59","article-title":"Influence of aetiology, clinical and histological features on survival in chronic active hepatitis: an analysis of 204 patients","volume":"62","author":"Keating","year":"1987","journal-title":"Q J Med"},{"key":"10.1016\/j.jhep.2015.06.030_b0925","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1111\/j.1478-3231.2005.01121.x","article-title":"Early treatment response predicts the need for liver transplantation in autoimmune hepatitis","volume":"25","author":"Tan","year":"2005","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2015.06.030_b0930","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1136\/gut.16.11.876","article-title":"Prednisone for chronic active liver disease: dose titration, standard dose, and combination with azathioprine compared","volume":"16","author":"Summerskill","year":"1975","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2015.06.030_b0935","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/j.1600-0676.1982.tb00184.x","article-title":"Azathioprine versus prednisone in non-alcoholic chronic liver disease (CLD). Relation to a serological classification","volume":"2","author":"Tage-Jensen","year":"1982","journal-title":"Liver"},{"key":"10.1016\/j.jhep.2015.06.030_b0940","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1002\/hep.23840","article-title":"Treatment response in patients with autoimmune hepatitis","volume":"52","author":"Schramm","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.06.030_b0945","doi-asserted-by":"crossref","first-page":"457","DOI":"10.3109\/00365520903555861","article-title":"Characteristics and long-term outcome of patients with autoimmune hepatitis related to the initial treatment response","volume":"45","author":"Werner","year":"2010","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.jhep.2015.06.030_b0950","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1111\/j.1365-2036.2006.03113.x","article-title":"Persistent elevation of serum alanine aminotransferase levels leads to poor survival and hepatocellular carcinoma development in type 1 autoimmune hepatitis","volume":"24","author":"Miyake","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2015.06.030_b0955","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1111\/j.1572-0241.2004.30457.x","article-title":"Factors predicting relapse and poor outcome in type I autoimmune hepatitis: role of cirrhosis development, patterns of transaminases during remission and plasma cell activity in the liver biopsy","volume":"99","author":"Verma","year":"2004","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2015.06.030_b0960","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1002\/hep.23924","article-title":"Application of the 2010 American Association for the study of liver diseases criteria of remission to a cohort of Italian patients with autoimmune hepatitis","volume":"52","author":"Muratori","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.06.030_b0965","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1053\/j.gastro.2010.06.046","article-title":"Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis","volume":"139","author":"Manns","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2015.06.030_b0970","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/j.1365-2036.1994.tb00334.x","article-title":"Oral budesonide for treatment of autoimmune chronic active hepatitis","volume":"8","author":"Danielsson","year":"1994","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2015.06.030_b0975","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1111\/j.1478-3231.2005.01122.x","article-title":"Budesonide in previously untreated autoimmune hepatitis","volume":"25","author":"Wiegand","year":"2005","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2015.06.030_b0980","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.3748\/wjg.v12.i9.1362","article-title":"Budesonide induces complete remission in autoimmune hepatitis","volume":"12","author":"Csepregi","year":"2006","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jhep.2015.06.030_b0985","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1053\/gast.2000.0010000001","article-title":"Failure of budesonide in a pilot study of treatment-dependent autoimmune hepatitis","volume":"119","author":"Czaja","year":"2000","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2015.06.030_b0990","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.3748\/wjg.v9.i12.2681","article-title":"Side effects of budesonide in liver cirrhosis due to chronic autoimmune hepatitis: influence of hepatic metabolism versus portosystemic shunts on a patient complicated with HCC","volume":"9","author":"Geier","year":"2003","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jhep.2015.06.030_b0995","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.autrev.2011.09.006","article-title":"Liver fibrosis may reduce the efficacy of budesonide in the treatment of autoimmune hepatitis and overlap syndrome","volume":"11","author":"Efe","year":"2012","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.jhep.2015.06.030_b1000","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1586\/egh.12.40","article-title":"Drug choices in autoimmune hepatitis: part A-Steroids","volume":"6","author":"Czaja","year":"2012","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2015.06.030_b1005","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1053\/jhep.2002.32485","article-title":"Sustained remission after corticosteroid therapy for type 1 autoimmune hepatitis: a retrospective analysis","volume":"35","author":"Czaja","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.06.030_b1010","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/hep.1840150208","article-title":"Prognostic features and role of liver transplantation in severe corticosteroid-treated autoimmune chronic active hepatitis","volume":"15","author":"Sanchez-Urdazpal","year":"1992","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.06.030_b1015","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1002\/hep.21787","article-title":"Features associated with treatment failure in type 1 autoimmune hepatitis and predictive value of the model of end-stage liver disease","volume":"46","author":"Montano-Loza","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.06.030_b1020","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1002\/hep.24141","article-title":"Early predictors of corticosteroid treatment failure in icteric presentations of autoimmune hepatitis","volume":"53","author":"Yeoman","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.06.030_b1025","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/0016-5085(88)90503-3","article-title":"Features reflective of early prognosis in corticosteroid-treated severe autoimmune chronic active hepatitis","volume":"95","author":"Czaja","year":"1988","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2015.06.030_b1030","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1002\/lt.21036","article-title":"Usefulness of corticosteroids for the treatment of severe and fulminant forms of autoimmune hepatitis","volume":"13","author":"Ichai","year":"2007","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2015.06.030_b1035","first-page":"221","article-title":"Failure of customary treatment in chronic active liver disease: causes and management","volume":"8","author":"Schalm","year":"1976","journal-title":"Ann Clin Res"},{"key":"10.1016\/j.jhep.2015.06.030_b1040","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1053\/j.gastro.2011.02.065","article-title":"Long-term outcomes of patients with autoimmune hepatitis managed at a nontransplant center","volume":"140","author":"Hoeroldt","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2015.06.030_b1045","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/S0168-8278(00)00095-7","article-title":"Duration of immunosuppressive therapy in autoimmune hepatitis","volume":"34","author":"Kanzler","year":"2001","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.06.030_b1050","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jhep.2009.02.026","article-title":"Rapidity of treatment response and outcome in type 1 autoimmune hepatitis","volume":"51","author":"Czaja","year":"2009","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.06.030_b1055","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1111\/j.1572-0241.2007.01153.x","article-title":"Improving the end point of corticosteroid therapy in type 1 autoimmune hepatitis to reduce the frequency of relapse","volume":"102","author":"Montano-Loza","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2015.06.030_b1060","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/0016-5085(81)90126-8","article-title":"Laboratory assessment of severe chronic active liver disease during and after corticosteroid therapy: correlation of serum transaminase and gamma globulin levels with histologic features","volume":"80","author":"Czaja","year":"1981","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2015.06.030_b1065","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.jhep.2014.10.018","article-title":"Patient selection based on treatment duration and liver biochemistry increases success rates after treatment withdrawal in autoimmune hepatitis","volume":"62","author":"Hartl","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.06.030_b1070","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1002\/hep.1840030510","article-title":"Relapse following treatment withdrawal in patients with autoimmune chronic active hepatitis","volume":"3","author":"Hegarty","year":"1983","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.06.030_b1075","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1056\/NEJM198101013040102","article-title":"Corticosteroid-treated chronic active hepatitis in remission: uncertain prognosis of chronic persistent hepatitis","volume":"304","author":"Czaja","year":"1981","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2015.06.030_b1080","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/0016-5085(87)90862-6","article-title":"Sustained remission after corticosteroid therapy of severe hepatitis B surface antigen-negative chronic active hepatitis","volume":"92","author":"Czaja","year":"1987","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2015.06.030_b1085","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1053\/jhep.2002.30991","article-title":"Current and novel immunosuppressive therapy for autoimmune hepatitis","volume":"35","author":"Heneghan","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.06.030_b1090","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1002\/hep.1840040409","article-title":"Complete resolution of inflammatory activity following corticosteroid treatment of HBsAg-negative chronic active hepatitis","volume":"4","author":"Czaja","year":"1984","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.06.030_b1095","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1111\/j.1572-0241.2007.01147.x","article-title":"Remission in autoimmune hepatitis: what is it, and can it ever be achieved?","volume":"102","author":"Al-Chalabi","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2015.06.030_b1100","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/j.1478-3231.2007.01444.x","article-title":"Consequences of treatment withdrawal in type 1 autoimmune hepatitis","volume":"27","author":"Montano-Loza","year":"2007","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2015.06.030_b1105","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1002\/hep.1840080414","article-title":"Maintenance of remission in autoimmune chronic active hepatitis with azathioprine after corticosteroid withdrawal","volume":"8","author":"Stellon","year":"1988","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.06.030_b1110","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1056\/NEJM199510123331502","article-title":"Azathioprine for long-term maintenance of remission in autoimmune hepatitis","volume":"333","author":"Johnson","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2015.06.030_b1115","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1056\/NEJM199510123331512","article-title":"Autoimmune hepatitis","volume":"333","author":"Meyer zum Buschenfelde","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2015.06.030_b1120","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/j.1552-4604.1990.tb03606.x","article-title":"Azathioprine metabolism: pharmacokinetics of 6-mercaptopurine, 6-thiouric acid and 6-thioguanine nucleotides in renal transplant patients","volume":"30","author":"Chan","year":"1990","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.jhep.2015.06.030_b1125","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/BF02220605","article-title":"The clinical pharmacology of 6-mercaptopurine","volume":"43","author":"Lennard","year":"1992","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.jhep.2015.06.030_b1130","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/S1542-3565(04)00344-1","article-title":"Azathioprine, 6-mercaptopurine in inflammatory bowel disease: pharmacology, efficacy, and safety","volume":"2","author":"Dubinsky","year":"2004","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2015.06.030_b1135","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0162-3109(00)00186-7","article-title":"Immunosuppressive drugs: the first 50years and a glance forward","volume":"47","author":"Allison","year":"2000","journal-title":"Immunopharmacology"},{"key":"10.1016\/j.jhep.2015.06.030_b1140","first-page":"351","article-title":"Azathioprine-induced myelosuppression due to thiopurine methyltransferase deficiency in a patient with autoimmune hepatitis","volume":"23","author":"Ben Ari","year":"1995","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.06.030_b1145","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/S1542-3565(04)00127-2","article-title":"Thiopurine methyltransferase activity influences clinical response to azathioprine in inflammatory bowel disease","volume":"2","author":"Cuffari","year":"2004","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2015.06.030_b1150","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S0168-8278(02)00214-3","article-title":"Thiopurine methyltransferase phenotype and genotype in relation to azathioprine therapy in autoimmune hepatitis","volume":"37","author":"Langley","year":"2002","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.06.030_b1155","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.jhep.2006.05.011","article-title":"Utility of thiopurine methyltransferase genotyping and phenotyping, and measurement of azathioprine metabolites in the management of patients with autoimmune hepatitis","volume":"45","author":"Heneghan","year":"2006","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.06.030_b1160","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1111\/apt.12381","article-title":"Review article: the management of autoimmune hepatitis beyond consensus guidelines","volume":"38","author":"Czaja","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2015.06.030_b1165","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1007\/s10620-006-9336-5","article-title":"Thiopurine methyltransferase deficiency and azathioprine intolerance in autoimmune hepatitis","volume":"51","author":"Czaja","year":"2006","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jhep.2015.06.030_b1170","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S0009-9236(97)90152-1","article-title":"Human thiopurine methyltransferase pharmacogenetics: gene sequence polymorphisms","volume":"62","author":"Otterness","year":"1997","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jhep.2015.06.030_b1175","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1136\/gut.52.1.140","article-title":"Safe treatment of thiopurine S-methyltransferase deficient Crohn\u2019s disease patients with azathioprine","volume":"52","author":"Kaskas","year":"2003","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2015.06.030_b1180","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1097\/00008571-199208000-00002","article-title":"Human liver thiopurine methyltransferase pharmacogenetics: biochemical properties, liver-erythrocyte correlation and presence of isozymes","volume":"2","author":"Szumlanski","year":"1992","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.jhep.2015.06.030_b1185","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jhep.2009.10.004","article-title":"Characterisation and utility of thiopurine methyltransferase and thiopurine metabolite measurements in autoimmune hepatitis","volume":"52","author":"Hindorf","year":"2010","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.06.030_b1190","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1111\/j.1572-0241.2006.00479.x","article-title":"Pregnancy in autoimmune hepatitis: outcome and risk factors","volume":"101","author":"Schramm","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2015.06.030_b1195","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1080\/00365520601155266","article-title":"Autoimmune hepatitis among fertile women: strategies during pregnancy and breastfeeding?","volume":"42","author":"Werner","year":"2007","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.jhep.2015.06.030_b1200","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1053\/gast.2003.50014","article-title":"The safety of 6-mercaptopurine for childbearing patients with inflammatory bowel disease: a retrospective cohort study","volume":"124","author":"Francella","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2015.06.030_b1205","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/ibd.22948","article-title":"Systematic review and meta-analysis on the effects of thiopurines on birth outcomes from female and male patients with inflammatory bowel disease","volume":"19","author":"Akbari","year":"2013","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.jhep.2015.06.030_b1210","first-page":"742","article-title":"Subsequent pregnancy (twin) in woman with autoimmunological hepatitis","volume":"76","author":"Adamowicz","year":"2005","journal-title":"Ginekol Pol"},{"key":"10.1016\/j.jhep.2015.06.030_b1215","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1002\/lt.20810","article-title":"Pregnancy outcome after liver transplantation: a single-center experience of 71 pregnancies in 45 recipients","volume":"12","author":"Christopher","year":"2006","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2015.06.030_b1220","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/0002-9378(67)90503-0","article-title":"Azathioprine (Imuran) and pregnancy","volume":"97","author":"Rosenkrantz","year":"1967","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.jhep.2015.06.030_b1225","doi-asserted-by":"crossref","first-page":"e89151","DOI":"10.1371\/journal.pone.0089151","article-title":"Pregnancy outcomes in liver and cardiothoracic transplant recipients: a UK national cohort study","volume":"9","author":"Mohamed-Ahmed","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jhep.2015.06.030_b1230","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.crohns.2010.10.005","article-title":"Long-term follow-up of babies exposed to azathioprine in utero and via breastfeeding","volume":"5","author":"Angelberger","year":"2011","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.jhep.2015.06.030_b1235","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1111\/j.1365-2036.2008.03843.x","article-title":"Azathioprine treatment during lactation","volume":"28","author":"Christensen","year":"2008","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2015.06.030_b1240","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1002\/hep.510250308","article-title":"Autoimmune hepatitis in childhood: a 20-year experience","volume":"25","author":"Gregorio","year":"1997","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.06.030_b1245","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1016\/0016-5085(93)90157-8","article-title":"Significance of HLA DR4 in type 1 autoimmune hepatitis","volume":"105","author":"Czaja","year":"1993","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2015.06.030_b1250","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0022-3476(84)80477-1","article-title":"Treatment of autoimmune chronic active hepatitis in childhood","volume":"104","author":"Maggiore","year":"1984","journal-title":"J Pediatr"},{"key":"10.1016\/j.jhep.2015.06.030_b1255","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1097\/00005176-199311000-00007","article-title":"Autoimmune hepatitis associated with anti-actin antibodies in children and adolescents","volume":"17","author":"Maggiore","year":"1993","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.jhep.2015.06.030_b1260","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1097\/01.mpg.0000232331.93052.dd","article-title":"Azathioprine monotherapy for maintenance of remission in pediatric patients with autoimmune hepatitis","volume":"43","author":"Banerjee","year":"2006","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.jhep.2015.06.030_b1265","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.jhep.2009.02.024","article-title":"Mycophenolate mofetil as rescue treatment for autoimmune liver disease in children: a 5-year follow-up","volume":"51","author":"Aw","year":"2009","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.06.030_b1270","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0022-3476(99)70339-2","article-title":"Efficacy of cyclosporin A in children with type 2 autoimmune hepatitis","volume":"135","author":"Debray","year":"1999","journal-title":"J Pediatr"},{"key":"10.1016\/j.jhep.2015.06.030_b1275","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/S0168-8278(99)80065-8","article-title":"Short-term cyclosporine induces a remission of autoimmune hepatitis in children","volume":"30","author":"Alvarez","year":"1999","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.06.030_b1280","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1023\/A:1010683817344","article-title":"Cyclosporin A is a promising alternative to corticosteroids in autoimmune hepatitis","volume":"46","author":"Malekzadeh","year":"2001","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jhep.2015.06.030_b1285","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1097\/01.mpg.0000235975.75120.38","article-title":"Follow-up of children with autoimmune hepatitis treated with cyclosporine","volume":"43","author":"Cuarterolo","year":"2006","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.jhep.2015.06.030_b1290","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jpeds.2013.05.042","article-title":"Budesonide versus prednisone with azathioprine for the treatment of autoimmune hepatitis in children and adolescents","volume":"163","author":"Woynarowski","year":"2013","journal-title":"J Pediatr"},{"key":"10.1016\/j.jhep.2015.06.030_b1295","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1111\/j.1572-0241.2007.01609.x","article-title":"Incidence of HAV and HBV infections and vaccination rates in patients with autoimmune liver diseases","volume":"103","author":"Worns","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2015.06.030_b1300","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1002\/hep.21074","article-title":"Distinctive clinical phenotype and treatment outcome of type 1 autoimmune hepatitis in the elderly","volume":"43","author":"Czaja","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.06.030_b1305","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.2169\/internalmedicine.46.0420","article-title":"Clinical features of Japanese elderly patients with type 1 autoimmune hepatitis","volume":"46","author":"Miyake","year":"2007","journal-title":"Intern Med"},{"key":"10.1016\/j.jhep.2015.06.030_b1310","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1111\/j.1365-2036.2005.02488.x","article-title":"Clinical features of type 1 autoimmune hepatitis in elderly Italian patients","volume":"21","author":"Granito","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2015.06.030_b1315","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/0168-8278(95)80226-6","article-title":"Histological grading and staging of chronic hepatitis","volume":"22","author":"Ishak","year":"1995","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.06.030_b1320","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/j.bone.2005.11.024","article-title":"Osteoporosis: a still increasing prevalence","volume":"38","author":"Reginster","year":"2006","journal-title":"Bone"},{"key":"10.1016\/j.jhep.2015.06.030_b1325","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1002\/art.22294","article-title":"Fracture risk with intermittent high-dose oral glucocorticoid therapy","volume":"56","author":"De Vries","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jhep.2015.06.030_b1330","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/BF02938618","article-title":"Prevention and treatment of glucocorticoid-induced osteoporosis","volume":"5","author":"Curtis","year":"2007","journal-title":"Curr Osteoporos Rep"},{"key":"10.1016\/j.jhep.2015.06.030_b1335","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/S0016-5085(03)01060-6","article-title":"American Gastroenterological Association medical position statement: osteoporosis in hepatic disorders","volume":"125","author":"American Gastroenterological Association","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2015.06.030_b1340","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1111\/j.1572-0241.2006.00571.x","article-title":"Do guidelines matter? Implementation of the ACG and AGA osteoporosis screening guidelines in inflammatory bowel disease (IBD) patients who meet the guidelines\u2019 criteria","volume":"101","author":"Kornbluth","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2015.06.030_b1345","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1007\/s10620-010-1130-8","article-title":"Bone health in a tertiary-care gastroenterology and hepatology population","volume":"55","author":"Long","year":"2010","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jhep.2015.06.030_b1350","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1002\/hep.21852","article-title":"Bone disorders in chronic liver disease","volume":"46","author":"Collier","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.06.030_b1355","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.jhep.2006.06.007","article-title":"Treatment of bone disorders in liver disease","volume":"45","author":"Pares","year":"2006","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.06.030_b1360","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.jhep.2014.05.021","article-title":"Prognosis of acute severe autoimmune hepatitis (AS-AIH): The role of corticosteroids in modifying outcome","volume":"61","author":"Yeoman","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.06.030_b1365","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1002\/hep.22894","article-title":"Liver failure as initial presentation of autoimmune hepatitis: clinical characteristics, predictors of response to steroid therapy, and outcomes","volume":"49","author":"Verma","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.06.030_b1370","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.3748\/wjg.v17.i16.2070","article-title":"Optimizing management in autoimmune hepatitis with liver failure at initial presentation","volume":"17","author":"Potts","year":"2011","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jhep.2015.06.030_b1375","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.jhep.2014.06.030","article-title":"Acute autoimmune hepatitis: many open questions","volume":"61","author":"Weiler-Normann","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.06.030_b1380","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1097\/00005176-200209000-00032","article-title":"Azathioprine metabolite measurements in the treatment of autoimmune hepatitis in pediatric patients: a preliminary report","volume":"35","author":"Rumbo","year":"2002","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.jhep.2015.06.030_b1385","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1097\/00042737-200412000-00028","article-title":"Therapeutic drug monitoring of thiopurine drugs in patients with inflammatory bowel disease or autoimmune hepatitis","volume":"16","author":"Wusk","year":"2004","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2015.06.030_b1390","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1002\/hep.25760","article-title":"Clinical significance of azathioprine metabolites for the maintenance of remission in autoimmune hepatitis","volume":"56","author":"Dhaliwal","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.06.030_b1395","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.jhep.2010.09.017","article-title":"Reactivation of autoimmune hepatitis during budesonide monotherapy, and response to standard treatment","volume":"54","author":"Lohse","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.06.030_b1400","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1111\/apt.12042","article-title":"Systematic review: managing suboptimal treatment responses in autoimmune hepatitis with conventional and nonstandard drugs","volume":"36","author":"Selvarajah","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2015.06.030_b1405","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1111\/j.1365-2036.2010.04241.x","article-title":"Review article: the modern management of autoimmune hepatitis","volume":"31","author":"Yeoman","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2015.06.030_b1410","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/j.cgh.2008.04.006","article-title":"A single center review of the use of mycophenolate mofetil in the treatment of autoimmune hepatitis","volume":"6","author":"Hlivko","year":"2008","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2015.06.030_b1415","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1111\/j.1572-0241.2008.02180.x","article-title":"Mycophenolate mofetil as second line therapy in autoimmune hepatitis?","volume":"103","author":"Hennes","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2015.06.030_b1420","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1155\/2010\/891252","article-title":"Mycophenolate mofetil for the treatment of autoimmune hepatitis in patients refractory or intolerant to conventional therapy","volume":"24","author":"Sharzehi","year":"2010","journal-title":"Can J Gastroenterol"},{"key":"10.1016\/j.jhep.2015.06.030_b1425","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1046\/j.1365-2036.2003.01754.x","article-title":"Effectiveness and safety of ciclosporin as therapy for autoimmune diseases of the liver in children and adolescents","volume":"19","author":"Sciveres","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2015.06.030_b1430","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/S0168-8278(05)80615-4","article-title":"Cyclosporine in the management of corticosteroid-resistant type I autoimmune chronic active hepatitis","volume":"21","author":"Sherman","year":"1994","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.06.030_b1435","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/j.1572-0241.1999.00807.x","article-title":"Cyclosporine therapy in patients with steroid resistant autoimmune hepatitis","volume":"94","author":"Fernandes","year":"1999","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2015.06.030_b1440","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1097\/01.mcg.0000139050.67178.be","article-title":"Efficacy of tacrolimus in the treatment of steroid refractory autoimmune hepatitis","volume":"38","author":"Aqel","year":"2004","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.jhep.2015.06.030_b1445","doi-asserted-by":"crossref","first-page":"3232","DOI":"10.3748\/wjg.v13.i23.3232","article-title":"Low-dose tacrolimus ameliorates liver inflammation and fibrosis in steroid refractory autoimmune hepatitis","volume":"13","author":"Larsen","year":"2007","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jhep.2015.06.030_b1450","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/j.1365-2036.2011.04749.x","article-title":"Use of tacrolimus in the treatment of autoimmune hepatitis: a single centre experience","volume":"34","author":"Tannous","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2015.06.030_b1455","first-page":"571","article-title":"Cyclophosphamide as alternative immunosuppressive therapy for autoimmune hepatitis\u2013report of three cases","volume":"35","author":"Kanzler","year":"1997","journal-title":"Z Gastroenterol"},{"key":"10.1016\/j.jhep.2015.06.030_b1460","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/S0168-8278(98)80128-1","article-title":"Successful treatment of refractory type 1 autoimmune hepatitis with methotrexate","volume":"29","author":"Burak","year":"1998","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.06.030_b1465","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1155\/2013\/512624","article-title":"Rituximab for the treatment of patients with autoimmune hepatitis who are refractory or intolerant to standard therapy","volume":"27","author":"Burak","year":"2013","journal-title":"Can J Gastroenterol"},{"key":"10.1016\/j.jhep.2015.06.030_b1470","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.jhep.2012.11.010","article-title":"Infliximab as a rescue treatment in difficult-to-treat autoimmune hepatitis","volume":"58","author":"Weiler-Normann","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.06.030_b1475","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.jhep.2014.01.032","article-title":"Anti-TNF-induced autoimmune hepatitis","volume":"61","author":"Borman","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.06.030_b1480","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.jhep.2014.03.008","article-title":"Reply to: \u201canti-TNF-induced autoimmune hepatitis\u201d","volume":"61","author":"Weiler-Normann","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.06.030_b1485","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1111\/j.1600-6143.2005.00801.x","article-title":"Rapamycin successfully treats post-transplant autoimmune hepatitis","volume":"5","author":"Kerkar","year":"2005","journal-title":"Am J Transplant"},{"key":"10.1016\/j.jhep.2015.06.030_b1490","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1016\/j.amjmed.2014.06.016","article-title":"Use of sirolimus in the treatment of refractory autoimmune hepatitis","volume":"127","author":"Chatrath","year":"2014","journal-title":"Am J Med"},{"key":"10.1016\/j.jhep.2015.06.030_b1495","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jaut.2013.08.004","article-title":"Autoimmune hepatitis: contrasts and comparisons in children and adults \u2013 A comprehensive review","volume":"46","author":"Floreani","year":"2013","journal-title":"J Autoimmun"},{"key":"10.1016\/j.jhep.2015.06.030_b1500","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1097\/01.mpg.0000239735.87111.ba","article-title":"Prospective analysis of nonadherence in autoimmune hepatitis: a common problem","volume":"43","author":"Kerkar","year":"2006","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.jhep.2015.06.030_b1505","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1177\/1367493504041868","article-title":"Improving transition: a qualitative study examining the attitudes of young people with chronic illness transferring to adult care","volume":"8","author":"Soanes","year":"2004","journal-title":"J Child Health Care"},{"key":"10.1016\/j.jhep.2015.06.030_b1510","doi-asserted-by":"crossref","first-page":"888","DOI":"10.12968\/bjon.2014.23.16.888","article-title":"Theory to reality: the role of the transition nurse coordinator","volume":"23","author":"Kelly","year":"2014","journal-title":"Br J Nurs"},{"key":"10.1016\/j.jhep.2015.06.030_b1515","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1053\/gast.1996.v110.pm8536867","article-title":"The successful treatment of autoimmune hepatitis with 6-mercaptopurine after failure with azathioprine","volume":"110","author":"Pratt","year":"1996","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2015.06.030_b1520","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.jhep.2005.10.017","article-title":"Long term outcome and response to therapy of primary biliary cirrhosis-autoimmune hepatitis overlap syndrome","volume":"44","author":"Chazouilleres","year":"2006","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.06.030_b1525","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1053\/jhep.2002.30902","article-title":"Primary biliary cirrhosis with additional features of autoimmune hepatitis: response to therapy with ursodeoxycholic acid","volume":"35","author":"Joshi","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.06.030_b1530","doi-asserted-by":"crossref","first-page":"3368","DOI":"10.3748\/wjg.14.3368","article-title":"Overlap syndromes among autoimmune liver diseases","volume":"14","author":"Rust","year":"2008","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jhep.2015.06.030_b1535","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.cgh.2013.09.021","article-title":"Factors associated with response to therapy and outcome of patients with primary biliary cirrhosis with features of autoimmune hepatitis","volume":"12","author":"Ozaslan","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2015.06.030_b1540","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1002\/hep.21229","article-title":"Development of autoimmune hepatitis in patients with typical primary biliary cirrhosis","volume":"44","author":"Poupon","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.06.030_b1545","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1111\/j.1572-0241.2005.41841.x","article-title":"Clinical course and outcome of autoimmune hepatitis\/primary sclerosing cholangitis overlap syndrome","volume":"100","author":"Floreani","year":"2005","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2015.06.030_b1550","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/j.1365-2036.2008.03722.x","article-title":"Autoimmune hepatitis overlap syndromes: an evaluation of treatment response, long-term outcome and survival","volume":"28","author":"Al-Chalabi","year":"2008","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2015.06.030_b1555","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1002\/lt.20910","article-title":"Recurrence of autoimmune liver disease after liver transplantation: a systematic review","volume":"12","author":"Gautam","year":"2006","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2015.06.030_b1560","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.jhep.2013.09.020","article-title":"Autoimmune liver disease, autoimmunity and liver transplantation","volume":"60","author":"Carbone","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.06.030_b1565","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1053\/jlts.2001.21449","article-title":"Recurrent autoimmune hepatitis after orthotopic liver transplantation","volume":"7","author":"Gonzalez-Koch","year":"2001","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2015.06.030_b1570","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1053\/jhep.2002.31167","article-title":"Response to steroids in de novo autoimmune hepatitis after liver transplantation","volume":"35","author":"Salcedo","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.06.030_b1575","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1111\/j.1572-0241.2002.05995.x","article-title":"Contribution of obesity to hepatitis C-related fibrosis progression","volume":"97","author":"Ortiz","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2015.06.030_b1580","doi-asserted-by":"crossref","first-page":"c912","DOI":"10.1136\/bmj.c912","article-title":"Million Women Study C. Body mass index and risk of liver cirrhosis in middle aged UK women: prospective study","volume":"340","author":"Liu","year":"2010","journal-title":"BMJ"},{"key":"10.1016\/j.jhep.2015.06.030_b1585","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jhep.2012.02.010","article-title":"EASL Clinical Practice Guidelines: management of chronic hepatitis B virus infection","volume":"57","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.06.030_b1590","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1086\/524082","article-title":"De novo autoimmune hepatitis during immune reconstitution in an HIV-infected patient receiving highly active antiretroviral therapy","volume":"46","author":"O\u2019Leary","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jhep.2015.06.030_b1595","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1097\/01.mcg.0000225591.08825.3e","article-title":"Three cases of autoimmune hepatitis in HIV-infected patients","volume":"42","author":"Puius","year":"2008","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.jhep.2015.06.030_b1600","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1089\/apc.2008.0149","article-title":"Autoimmune hepatitis in the HIV-infected patient: a therapeutic dilemma","volume":"23","author":"Wan","year":"2009","journal-title":"AIDS Patient Care STDS"},{"key":"10.1016\/j.jhep.2015.06.030_b1605","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jhep.2014.09.010","article-title":"Unmet clinical need in autoimmune liver diseases","volume":"62","author":"Dyson","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.06.030_b1610","doi-asserted-by":"crossref","DOI":"10.1186\/1750-1172-7-S2-A9","article-title":"Developing a national plan for rare diseases in Germany through concerted action: the national action league for people with rare diseases","volume":"7","author":"H\u00e9on-Klin","year":"2012","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.jhep.2015.06.030_b1615","doi-asserted-by":"crossref","first-page":"73","DOI":"10.2165\/00019053-200220003-00007","article-title":"The Agrenska centre: a socioeconomic case study of rare diseases","volume":"20","author":"Olauson","year":"2002","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.jhep.2015.06.030_b1620","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1200\/JCO.1999.17.1.371","article-title":"Can 40 seconds of compassion reduce patient anxiety?","volume":"17","author":"Fogarty","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2015.06.030_b1625","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S1089-3261(02)00030-2","article-title":"Medical and economic impact of autoimmune hepatitis","volume":"6","author":"Talwalkar","year":"2002","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.jhep.2015.06.030_b1630","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s11136-006-9131-y","article-title":"Generic and disease-specific health related quality of life of liver patients with various aetiologies: a survey","volume":"16","author":"van der Plas","year":"2007","journal-title":"Qual Life Res"},{"key":"10.1016\/j.jhep.2015.06.030_b1635","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1097\/MPG.0b013e31829ef82c","article-title":"Health-related quality of life in children with autoimmune liver disease","volume":"57","author":"Gulati","year":"2013","journal-title":"J Pediatr Gastroenterol Nutr"}],"updated-by":[{"DOI":"10.1016\/j.jhep.2015.09.016","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000}}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827815004584?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827815004584?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,10]],"date-time":"2024-06-10T21:14:20Z","timestamp":1718054060000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827815004584"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":327,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["S0168827815004584"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2015.06.030","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2015,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"EASL Clinical Practice Guidelines: Autoimmune hepatitis","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2015.06.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}